Literature DB >> 15102617

Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments.

Amy J Davidoff1, Meredith M Mason, Michael B Davidson, Marybeth W Carmody, Kadon K Hintz, Loren E Wold, Deborah A Podolin, Jun Ren.   

Abstract

We recently identified cardiomyocyte dysfunction in the early stage of type 2 diabetes (i.e., diet-induced insulin resistance). The present investigation was designed to determine whether a variety of clinically relevant interventions are sufficient to prevent and reverse cardiomyocyte dysfunction in sucrose (SU)-fed insulin-resistant rats. Subsets of animals were allowed to exercise (free access to wheel attached to cage) or were treated with bezafibrate in drinking water to determine whether these interventions would prevent the adverse effects of SU feeding on cardiomyocyte function. After 6-8 wk on diet and treatment, animals were surgically prepared to assess whole body insulin sensitivity (intravenous glucose tolerance test), and isolated ventricular myocyte mechanics were evaluated (video edge recording). SU feeding produced hyperinsulinemia and hypertriglyceridemia, with euglycemia, and induced characteristic whole body insulin resistance. Both exercise and bezafibrate treatment prevented these metabolic abnormalities. Ventricular myocyte shortening and relengthening were slower in SU-fed rats (42-63%) compared with starch (ST)-fed controls, and exercise or bezafibrate completely prevented cardiomyocyte dysfunction in SU-fed rats. In separate cohorts of animals, after 5 wk of SU feeding, animals were either switched back to an ST diet or given menhaden oil for an additional 7-9 wk to determine whether the cardiomyocyte dysfunction was reversible. Both interventions have previously been shown to have favorable metabolic effects, and both improved myocyte mechanics, but only the ST diet reversed all indications of cardiomyocyte dysfunction induced by SU feeding. Thus phenotypic changes in cardiomyocyte mechanics associated with early stages of type 2 diabetes were found to be both preventable and reversible with clinically relevant treatments, suggesting that the cellular processes contributing to this dysfunction are modifiable.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102617     DOI: 10.1152/ajpendo.00358.2003

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  21 in total

1.  Metallothionein alleviates cardiac contractile dysfunction induced by insulin resistance: role of Akt phosphorylation, PTB1B, PPARgamma and c-Jun.

Authors:  C X Fang; F Dong; B H Ren; P N Epstein; J Ren
Journal:  Diabetologia       Date:  2005-09-20       Impact factor: 10.122

Review 2.  Altered cardiac calcium handling in diabetes.

Authors:  Darrell D Belke; Wolfgang H Dillmann
Journal:  Curr Hypertens Rep       Date:  2004-12       Impact factor: 5.369

3.  Cardiac overexpression of catalase rescues cardiac contractile dysfunction induced by insulin resistance: Role of oxidative stress, protein carbonyl formation and insulin sensitivity.

Authors:  F Dong; C X Fang; X Yang; X Zhang; F L Lopez; J Ren
Journal:  Diabetologia       Date:  2006-04-04       Impact factor: 10.122

Review 4.  Oxidative stress as a mechanism of added sugar-induced cardiovascular disease.

Authors:  Kailash Prasad; Indu Dhar
Journal:  Int J Angiol       Date:  2014-12

Review 5.  Animal models of insulin resistance and heart failure.

Authors:  Mauricio Velez; Smita Kohli; Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

Review 6.  Heart Failure in Type 2 Diabetes Mellitus.

Authors:  Helena C Kenny; E Dale Abel
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

Review 7.  Metabolic dysfunction in diabetic cardiomyopathy.

Authors:  Michael Isfort; Sarah C W Stevens; Stephen Schaffer; Chian Ju Jong; Loren E Wold
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

8.  Cardiomyocyte dysfunction in insulin-resistant rats: a female advantage.

Authors:  M L Schwanke; K Dutta; D A Podolin; A J Davidoff
Journal:  Diabetologia       Date:  2006-03-16       Impact factor: 10.122

Review 9.  Advanced glycation end products: role in pathology of diabetic cardiomyopathy.

Authors:  Vijaya Lakshmi Bodiga; Sasidhar Reddy Eda; Sreedhar Bodiga
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

10.  Pioglitazone provides beneficial effect in metabolic syndrome rats via affecting intracellular Na+ Dyshomeostasis.

Authors:  Ayca Bilginoglu; Makbule Fulya Tutar Selcuk; Hilal Nakkas; Belma Turan
Journal:  J Bioenerg Biomembr       Date:  2018-10-25       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.